

# Treatment for Genotype 1

	Untreated for HCV	Treated previously for HCV	Interferon Ineligible or Intolerant
Without Cirrhosis	<p><b>Harvoni (Ledipasvir/Sofosbuvir)</b> <b>8 weeks</b></p> <p><b>Daklinza (Daclatasvir) + Sovaldi (Sofosbuvir)</b> <b>12 Weeks</b> - Recommended by NICE only if the patient has significant fibrosis</p> <p><b>1a</b> <b>Viekirax (ombitasvir/paritaprevir/ritonavir) with Exviera (dasabuvir) and ribavirin</b> <b>12 weeks</b></p> <p><b>1b</b> <b>Viekirax (ombitasvir/paritaprevir/ritonavir) with Exviera (dasabuvir) only</b> <b>12 weeks</b></p>	<p><b>Harvoni (Ledipasvir/Sofosbuvir)</b> <b>12 weeks</b></p> <p><b>Daklinza (Daclatasvir) + Sovaldi (Sofosbuvir)</b> <b>12 Weeks</b> - Recommended by NICE only if the patient has significant fibrosis</p> <p><b>1a</b> <b>Viekirax (ombitasvir/paritaprevir/ritonavir) with Exviera (dasabuvir) and ribavirin</b> <b>12 weeks</b></p> <p><b>1b</b> <b>Viekirax (ombitasvir/paritaprevir/ritonavir) with Exviera (dasabuvir) only</b> <b>12 weeks</b></p>	<p><b>Daklinza (Daclatasvir) + Sovaldi (Sofosbuvir)</b> <b>12 Weeks</b> - Recommended by NICE only if the patient has significant fibrosis</p> <p><b>1a</b> <b>Viekirax (ombitasvir/paritaprevir/ritonavir) with Exviera (dasabuvir) and ribavirin</b> <b>12 weeks</b></p> <p><b>1b</b> <b>Viekirax (ombitasvir/paritaprevir/ritonavir) with Exviera (dasabuvir) only</b> <b>12 weeks</b></p>
With Compensated Cirrhosis	<p><b>Harvoni (Ledipasvir/Sofosbuvir)</b> <b>12 weeks</b></p> <p><b>Viekirax (ombitasvir/paritaprevir/ritonavir) with Exviera (dasabuvir) and ribavirin</b> <b>1a = 24 weeks</b> <b>1b = 12 weeks</b></p>	<p><b>Harvoni (Ledipasvir/Sofosbuvir)<sup>†</sup></b> <b>12 weeks</b></p> <p><b>Viekirax (ombitasvir/paritaprevir/ritonavir) with Exviera (dasabuvir) and ribavirin</b> <b>1a = 24 weeks</b> <b>1b = 12 weeks</b></p>	<p><b>DDaklinza (Daclatasvir) + Sovaldi (Sofosbuvir) (with or without Ribavirin)</b> <b>24 weeks</b></p> <p><b>Viekirax (ombitasvir/paritaprevir/ritonavir) with Exviera (dasabuvir) and ribavirin</b> <b>1a = 24 weeks</b> <b>1b = 12 weeks</b></p>

<sup>†</sup>If all of the following criteria are met: Child–Pugh class A, platelet count of 75,000/mm<sup>3</sup> or more, no features of portal hypertension, no history of an HCV-associated decompensation episode, not previously treated with an NSSA inhibitor.

### Treatment for Genotype 3

	Untreated for HCV	Treated previously for HCV	Interferon Ineligible or Intolerant
Without Cirrhosis			<b>Daklinza (Daclatasvir) + Sovaldi (Sofosbuvir)</b> <b>12 weeks</b> (only if significant fibrosis present)
With Cirrhosis			<b>Daklinza (Daclatasvir) + Sovaldi (Sofosbuvir) + ribavirin</b> <b>24 weeks</b>

### Treatment for Genotype 4

	Untreated for HCV	Treated previously for HCV	Interferon Ineligible or Intolerant
Without Cirrhosis	<b>Viekirax</b> (ombitasvir/paritaprevir/ritonavir) and ribavirin <b>12 weeks</b>	<b>Viekirax</b> (ombitasvir/paritaprevir/ritonavir) and ribavirin <b>12 weeks</b>  <b>Daklinza</b> (daclatasvir) + <b>Sovaldi</b> (Sofosbuvir) <b>12 weeks</b> (if significant fibrosis present)  <b>Harvoni</b> (Ledipasvir/Sofosbuvir) <b>12 weeks</b>	<b>Viekirax</b> (ombitasvir/paritaprevir/ritonavir) and ribavirin <b>12 weeks</b>  <b>Daklinza</b> (Daclatasvir) + <b>Sovaldi</b> (Sofosbuvir) <b>12 weeks</b> (if significant fibrosis present)
With Compensated Cirrhosis	<b>Viekirax</b> (ombitasvir/paritaprevir/ritonavir) and ribavirin <b>24 weeks</b>  <b>Harvoni</b> (Ledipasvir/Sofosbuvir) <b>12 weeks</b>  <b>Daklinza</b> (daclatasvir) + <b>Peg-Interferon Alfa + Ribavirin</b> <b>24 Weeks</b> -Recommended only if the person has significant fibrosis or compensated cirrhosis	<b>Viekirax</b> (ombitasvir/paritaprevir/ritonavir) and ribavirin <b>24 weeks</b>  <b>Harvoni</b> (Ledipasvir/Sofosbuvir) - see NOTE A <b>12 weeks</b>  <b>Daklinza</b> (daclatasvir) + <b>Peg-Interferon Alfa + Ribavirin</b> <b>24 weeks</b> - Recommended only if the person has significant fibrosis or compensated cirrhosis	<b>Viekirax</b> (ombitasvir/paritaprevir/ritonavir) and ribavirin <b>24 weeks</b>  <b>Daklinza</b> (daclatasvir) + <b>Sovaldi</b> (sofosbuvir) (with or without ribavirin) <b>24 weeks</b> - Recommended only if the person has significant fibrosis

\*If all of the following criteria are met: Child-Pugh class A, platelet count of 75,000/mm<sup>3</sup> or more, no features of portal hypertension, no history of an HCV-associated decompensation episode, not previously treated with an NSSA inhibitor.

[Hepatitis C \(chronic\) - ledipasvir-sofosbuvir \[ID742\]: https://www.nice.org.uk/guidance/indevelopment/gid-tag484](https://www.nice.org.uk/guidance/indevelopment/gid-tag484)

[Hepatitis C \(chronic\) - ombitasvir/paritaprevir/ritonavir \(with or without dasabuvir\) \[ID731\]: https://www.nice.org.uk/guidance/indevelopment/gid-tag483](https://www.nice.org.uk/guidance/indevelopment/gid-tag483)

[Hepatitis C \(chronic\)-daclatasvir \[ID766\]: https://www.nice.org.uk/guidance/indevelopment/gid-tag487](https://www.nice.org.uk/guidance/indevelopment/gid-tag487)